<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298307</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC18-REPLICA</org_study_id>
    <nct_id>NCT04298307</nct_id>
  </id_info>
  <brief_title>Registry of Coronary Lithotripsy in Spain.</brief_title>
  <acronym>REPLICA</acronym>
  <official_title>Prospective, Multicenter, Observational, Single-arm Registry of Coronary Lithotripsy for the Management of Calcified Lesions in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación EPIC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación EPIC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REPLICA TRIAL tries to assess the intracoronary lithotripsy safety and efficacy profiles
      in real-world patients with calcified coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REPLICA TRIAL tries to assess the intracoronary lithotripsy safety and efficacy profiles
      in real-world patients with calcified coronary artery disease requiring percutaneous
      revascularization with stent implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Assessment of procedural success defined as angiographic results (TIMI grade 3 and residual stenosis &lt; 20% without in-hospital complications ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Major Cardiovascular Adverse Events (MACE), defined as a composite of cardiac death, target vessel related nonfatal infarction or need for unplanned target vessel revascularization during hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Major Cardiovascular Adverse Events (MACE), defined as a composite of cardiac death, target vessel related nonfatal infarction or need for unplanned target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual stenosis</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Assessment of angiographic stenosis during stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all cause)</measure>
    <time_frame>12 months</time_frame>
    <description>Death (all cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (cardiovascular)</measure>
    <time_frame>12 months</time_frame>
    <description>Death (cardiovascular)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Myocardial Infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Non-fatal Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Target Vessel Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis of target lesion</measure>
    <time_frame>12 months</time_frame>
    <description>Stent thrombosis of target lesion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Vascular Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Patients with calcified coronary artery disease</arm_group_label>
    <description>Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary lithotripsy (ICL)</intervention_name>
    <description>ICL using the Shockwave catheter.</description>
    <arm_group_label>Patients with calcified coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be scheduled to undergo a intracoronary lithotripsy procedure using the
        Shockwave catheter (Shockwave Medical, Fremont, CA).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age.

          -  Patients with calcified coronary artery disease requiring percutaneous
             revascularization with stent implantation who, at the operator's discretion and
             according to the hospital routine clinical practice, require an ICL with the Shockwave
             catheter.

          -  The patients have been informed of the study characteristics and have given their
             written informed consent.

        Exclusion Criteria:

          -  Refusal to participate in this study.

          -  Patients whose life expectancy is &lt; 1 year.

          -  Patients with hemodynamic instability with Killip class III or IV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Belén Cid, MD, PhD</last_name>
    <phone>+34981950000</phone>
    <email>belcid77@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fundacion Epic</last_name>
    <phone>+34987876135</phone>
    <email>iepic@fundacionepic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Luz</name>
      <address>
        <city>Madrid</city>
        <zip>28003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Central de La Defensa</name>
      <address>
        <city>Madrid</city>
        <zip>28047</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Brinton TJ, Ali ZA, Hill JM, Meredith IT, Maehara A, Illindala U, Lansky A, Götberg M, Van Mieghem NM, Whitbourn R, Fajadet J, Di Mario C. Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses. Circulation. 2019 Feb 5;139(6):834-836. doi: 10.1161/CIRCULATIONAHA.118.036531.</citation>
    <PMID>30715944</PMID>
  </reference>
  <reference>
    <citation>Ali ZA, Nef H, Escaned J, Werner N, Banning AP, Hill JM, De Bruyne B, Montorfano M, Lefevre T, Stone GW, Crowley A, Matsumura M, Maehara A, Lansky AJ, Fajadet J, Di Mario C. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study. Circ Cardiovasc Interv. 2019 Oct;12(10):e008434. doi: 10.1161/CIRCINTERVENTIONS.119.008434. Epub 2019 Sep 25.</citation>
    <PMID>31553205</PMID>
  </reference>
  <reference>
    <citation>Wong B, El-Jack S, Newcombe R, Glenie T, Armstrong G, Khan A. Shockwave Intravascular Lithotripsy for Calcified Coronary Lesions: First Real-World Experience. J Invasive Cardiol. 2019 Mar;31(3):46-48. Epub 2019 Feb 15.</citation>
    <PMID>30765621</PMID>
  </reference>
  <reference>
    <citation>Vilalta V, Rodriguez-Leor O, Cid-Alvarez B, et al. Intracoronary Lithotripsy in a High-risk Real-world Population: First Experience in Severely Calcified, Complex Coronary Lesions. REC Interv Cardiol 2019; in press.</citation>
  </reference>
  <reference>
    <citation>Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries Td, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart. 2014 Aug;100(15):1158-64. doi: 10.1136/heartjnl-2013-305180. Epub 2014 May 20.</citation>
    <PMID>24846971</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracoronary lithotripsy</keyword>
  <keyword>Calcified lesions</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

